Nectin2 KO and KD HCC mouse models consistently elicited tumors of reduced size, restored T cell infiltration, and alleviated T cell exhaustion, further exemplifying the therapeutic potential of targeting TIGIT–NECTIN2 axis, either as monotherapy or in combination with other drugs to treat advanced HCC. Here, NECTIN2 is linked to hepatocellular carcinoma.